Return to study ST000138 main page
MB Sample ID: SA007809
| Local Sample ID: | PF0266 |
| Subject ID: | SU000157 |
| Subject Type: | Human |
| Subject Species: | Homo sapiens |
| Taxonomy ID: | 9606 |
| Human Inclusion Criteria: | Participants with a baseline fasting glucose < 100 mg/dl and a fasting glucose ? 100 mg/dl at the end of atenolol treatment are considered to have developed IFG. Participants with a baseline fasting glucose < 100 mg/dl and a fasting glucose that remained < 100 mg/dl at the end of atenolol treatment are considered to have not developed IFG. |
| Human Exclusion Criteria: | Participants with a fasting glucose ? 100 mg/dl at baseline are excluded from this study. |
| Species Group: | Human |
Select appropriate tab below to view additional metadata details:
Treatment:
| Treatment ID: | TR000159 |
| Treatment Summary: | Atenolol was initiated at 50mg, and titrated to 100mg, based on BP > 120/70 mmHg and tolerability. Blood samples were collected prior to initiation of atenolol treatment and after at least 6 weeks on the final dose. Blood samples were spun and serum and plasma fractions stored at -80C. Treatment: Intervention Treatment Compound: Atenolol Treatment Dose: 50mg titrated to 100mg based on BP and tolerability Treatment Dose Duration: Minimum of 6 weeks |
